Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
fesoterodine fumarate | ANDA | 2023-11-07 |
toviaz | New Drug Application | 2023-10-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Expiration | Code | ||
---|---|---|---|
FESOTERODINE FUMARATE, TOVIAZ, PFIZER | |||
2024-12-17 | PED | ||
2024-06-17 | I-861 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 7 | 4 | 12 | 14 | 12 | 49 |
Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | — | — | 2 | 1 | 4 |
Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | 1 | 1 | — | 2 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Adenocarcinoma | D000230 | — | — | — | — | — | 1 | — | 1 |
Urinary bladder neck obstruction | D001748 | EFO_1000840 | N32.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | 2 | — | — | 2 |
Nocturia | D053158 | — | R35.1 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Autonomic dysreflexia | D020211 | EFO_1001762 | G90.4 | — | 1 | — | — | — | 1 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
Stress urinary incontinence | D014550 | HP_0010992 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Food | D005502 | — | STY/T168 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | — | 4 | 4 |
Iron deficiencies | D000090463 | — | E61.1 | — | — | — | — | 3 | 3 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
Urinary bladder diseases | D001745 | — | N32.9 | — | — | — | — | 1 | 1 |
Drug common name | Fesoterodine |
INN | fesoterodine |
Description | Fesoterodine is a diarylmethane. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1 |
PDB | — |
CAS-ID | 286930-02-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1201764 |
ChEBI ID | — |
PubChem CID | 6918558 |
DrugBank | DB06702 |
UNII ID | 621G617227 (ChemIDplus, GSRS) |